London's COMPASS Pathways gets $285M funding boost to advance Psilocybin therapy for mental health — TFN

COMPASS Pathways, a London-based biotech startup, has secured $285 million in funding to advance its psilocybin therapy for mental health conditions. The funding, led by TCGX and Aisling Capital, will be used for phase 3 clinical trials, commercial planning, and research. The company aims to bring potentially transformative treatment options to patients in need.

COMPASS Pathways Raises $285 Million for Psilocybin Therapy

COMPASS Pathways is a UK-based biotech startup working in the mental health treatment sector, focused on developing and providing psilocybin-assisted therapy for mental health conditions.

A UK-based biotech startup developing psilocybin-assisted therapy for mental health conditions.

2 years ago

COMPASS Pathways Raises $285 Million for Psilocybin Therapy

Covered on